Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2009;40:3631-3634
Published online before print September 17, 2009, doi: 10.1161/STROKEAHA.109.564096
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Stroke: November 2009, Volume 40, Number 11
Right arrow All Versions of this Article:
40/11/3631    most recent
STROKEAHA.109.564096v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tsivgoulis, G.
Right arrow Articles by Alexandrov, A. V.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsivgoulis, G.
Right arrow Articles by Alexandrov, A. V.
Related Collections
Right arrow Thrombolysis

(Stroke. 2009;40:3631.)
© 2009 American Heart Association, Inc.


Research Letters

Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage

Georgios Tsivgoulis, MD, FESO; James L. Frey, MD; Murray Flaster, MD, PhD; Vijay K. Sharma, MD; Annabelle Y. Lao, MD; Steven L. Hoover, MD; Wei Liu, MD; Elefterios Stamboulis, MD; Anne W. Alexandrov, PhD; Marc D. Malkoff, MD Andrei V. Alexandrov, MD

From the Stroke Program (G.T., J.L.F., M.F., A.Y.L., S.L.H., W.L., A.W.A., M.D.M., A.V.A.), Barrow Neurological Institute, Phoenix, Ariz; the Comprehensive Stroke Center (G.T., V.K.S., A.W.A., A.V.A.), University of Alabama at Birmingham, Birmingham, Ala; the Department of Neurology (G.T.), Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece; the Division of Neurology (V.K.S.), Department of Medicine, National University Hospital, Singapore, Singapore; and the Second Department of Neurology (E.S.), University of Athens, School of Medicine, Athens, Greece.

Correspondence to Georgios Tsivgoulis, MD, FESO, Comprehensive Stroke Center, University of Alabama at Birmingham, RWUH M226, 1530 3rd Avenue S, Birmingham, AL 35294-3280. E-mail tsivgoulisgiorg{at}yahoo.gr

Background and Purpose— From small pilot studies, uncontrolled pretreatment systolic blood pressure >185 mm Hg and diastolic blood pressure >110 mm Hg in patients with acute ischemic stroke were introduced in the National Institute of Neurological Diseases and Stroke rtPA Stroke Study as a contraindication for thrombolysis. We sought to determine if pretreatment blood pressure protocol violations in patients with acute ischemic stroke receiving intravenous tissue plasminogen activator are related to the subsequent risk of symptomatic intracranial hemorrhage (sICH).

Methods— We reviewed medical records of consecutive ischemic stroke admissions treated with intravenous thrombolysis over a 10-year period at our tertiary care hospital. The National Institutes of Health Stroke Scale score on admission was used to determine baseline stroke severity. The closest documented blood pressure values to the time of tissue plasminogen activator bolus (range, 0 to 10 minutes) were considered as pretreatment blood pressure. Pretreatment blood pressure protocol violations were identified as systolic blood pressure >185 or diastolic blood pressure >110 mm Hg prebolus. sICH was defined as brain imaging evidence of intracranial hemorrhage with clinical worsening by the National Institutes of Health Stroke Scale score increase of ≥4 points.

Results— Among 510 patients with ischemic stroke treated with intravenous tissue plasminogen activator (282 men; mean age, 65±15 years), sICH occurred in 31 patients (6.1%). Blood pressure protocol violations were present in 63 patients (12.4%) and they were more frequent in patients with sICH (26% versus 12%; P=0.019). After adjusting for demographic characteristics, onset-to-treatment time, baseline National Institutes of Health Stroke Scale, stroke risk factors and medications, pretreatment blood pressure protocol violations were independently associated with a higher likelihood of sICH (OR, 2.59; 95% CI, 1.07 to 6.25; P=0.034).

Conclusions— These data support current guidelines advising not to use intravenous tissue plasminogen activator when pretreatment blood pressure exceeds the prespecified thresholds by showing that blood pressure protocol violations are independently associated with a higher likelihood of sICH.


Key Words: blood pressure • intracranial hemorrhage • outcome • stroke • thrombolysis • tPA